Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3

Watchlist Manager
Ouro Fino Saude Animal Participacoes SA Logo
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Watchlist
Price: 22.89 BRL 1.28% Market Closed
Market Cap: 1.2B BRL

Ouro Fino Saude Animal Participacoes SA
Investor Relations

Ouro Fino Saúde Animal Participações SA engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals. The firm manufactures veterinary products using scientific technology in the Company's laboratories. The firm's products are divided into six sectors: Wholesale, Birds, Cattle, Equine, Pet and Pigs. The Wholesale area is divided into four lines: Anti-Mastiticos, producing antibiotics killing bacteria and lumps; Antimicrobial, which focuses on the treatment of bacterial infectious diseases; Ectoparasiticides, concentrated on insect repellent products, and Endectocides, which is the treatment and control of internal and external diseases of cattle, sheep and swine parasites. There is also one additional line of products divided for additives, biological, inoculants, diagnostic kit, probiotics, silage and other supplements, among others.

Show more
Loading

Earnings Calls

2025 Q3
Jan 16, 2025
Show Transcript
Show Presentation
Show Presentation
Previous
Next
Strong financial performance with growth in digital services and retail
2025 Q3
Jan 16, 2025

Reliance Industries reported robust growth, with Q3 operating revenues up 19.4% year-on-year, totaling INR 33,074 crores. EBITDA increased by 18.8% to INR 16,585 crores, driven by higher data consumption and festive demand. The digital segment thrived, adding 3.3 million subscribers, pushing the total to 482.1 million, while ARPU rose 12% to INR 203.3. Retail revenues reached INR 90,000 crores, up 18.4% quarter-on-quarter, aided by strong festive sales. In O2C, EBITDA grew 2.4% year-on-year at INR 14,400 crores. The outlook remains positive, with ongoing investments expected to support further growth across segments.

Show Full Analysis

Management

Mr. Kleber Cesar Silveira Gomes
CEO & Member of Executive Board
No Bio Available
Mr. Marcelo Da Silva
CFO, Member of Executive Board & Chief Investor Relations Officer
No Bio Available
Mr. Tetsuhiko Hiramatsu
Member of Executive Board
No Bio Available
Angelo Melo
Director - Strategic Development & New Business
No Bio Available
Bruno Menegazzo
Supervisor of the Investor Relations Area
No Bio Available

Contacts

Address
SAO PAULO
Rodovia Anhanguera SP 330, Km 298, Distrito Industrial, Cravinhos
Contacts